Acurx Posts Quarterly Loss of $2.6 Million as Research Spending Rises

Key Facts

Acurx Pharmaceuticals reported on November 12 results for the third quarter ended September 30, 2026, posting a net loss of $2.6 million, or $0.49 per diluted share. The net loss was higher than the $2.0 million reported in the same period of 2025, while the loss per share declined from $1.23 to $0.49. The figures moved in different directions because the share count used to calculate the loss per share changed. The results included no documented comparison with analysts’ expectations. Verified information on the stock’s movement during the results announcement session is also unavailable, so this report is limited to the financial performance and operational developments announced by the company.

Research and development expenses rose to $1.1 million in the third quarter from $0.4 million in the same quarter of 2025. The company attributed the $0.7 million increase mainly to consulting costs related to a new trial program for recurrent infections. General and administrative expenses, meanwhile, fell to $1.5 million from $1.6 million, a decrease of $0.1 million. The figures show that higher development spending was accompanied by a modest reduction in administrative expenses, while the company continued to report a quarterly loss. The trial-related spending coincided with the start of patient enrollment in the PATHFINDER program at the end of September.

The company said it began enrolling patients in PATHFINDER on September 29, 2026, and the trial is targeting about 20 patients with multiple recurrences of Clostridioides difficile infection. Acurx described the trial as fully funded and said its success could strengthen the profile of ibezapolstat. According to the company, this could enable a pivotal Phase 3 study for recurrent infections under the U.S. Food and Drug Administration’s pathway for antibacterial and antifungal drugs for limited populations. This pathway differs from the ASPIRE trial, which targets acute infections. A move to a Phase 3 study remains contingent on the PATHFINDER results, according to the company’s presentation.

On liquidity, Acurx ended the third quarter with $9.7 million in cash, compared with $7.6 million on December 31, 2025. During the quarter, the company raised about $1.5 million in gross proceeds through an equity line of credit. For the first nine months of 2026, the net loss was $6.5 million, compared with $6.4 million in the corresponding period of 2025. The diluted loss per share for the period narrowed to $1.59 from $5.01. Research and development expenses for the nine months totaled $2.5 million, compared with $1.6 million, an increase of $0.9 million that the company attributed mainly to costs for the recurrent infection trial program.

In an earlier update in August 2026, the company said it had received conditional acceptance from the U.S. Food and Drug Administration and a trademark allowance from the U.S. Patent and Trademark Office for the proposed name of ibezapolstat. It also said in its second-quarter results that the drug was ready to advance to international Phase 3 trials, subject to adequate funding. In its current update, the company said the FDA is open to discussing the totality of evidence from the ibezapolstat program at a pre-new drug application meeting. The company linked that discussion to completion of the Phase 3 ASPIRE trial and data from the ongoing PATHFINDER trial. It added that the focus would be on whether the efficacy data are sufficiently robust to support a registration application.

The chief executive officer and chief financial officer were scheduled to hold a call to discuss the results and provide a business update on November 12, 2026, at 8:00 a.m. Eastern Time. The call is taking place on the day the results are announced, with operational developments focused on the ibezapolstat program and the ASPIRE and PATHFINDER trials. The company ties next steps to the trial results and the FDA’s review of the clinical evidence. The information provided did not specify a later date for completing PATHFINDER or for the pre-new drug application meeting. The next announced step therefore remains completion of the clinical data and discussion of the evidence as a whole with the regulator.